Table 2. Second-line systemic treatment groups.
Group | Number of patients (%) | Median PFS (months; CI) | Median OS (months; CI) |
---|---|---|---|
GEM-P | 11 (19.6) | 3.8 (2.3-8.2) | 12.3 (10-40.7) |
GEM-FU | 16 (28.6) | 2.6 (1.8-3.9) | 15.1 (8.6-22) |
FU-combo | 21 (37.5) | 2.5 (1.8-4.6) | 14.7 (9.6-23.5) |
Other* | 8 (14.3) | 2.8 (2-9) | 20.9 (1.8-N/A) |
*GEM-P, gemcitabine plus platinum; GEM-FU, gemcitabine plus fluoropyrimidine; FU-combo, fluoropyrimidine combination; CI, confidence interval.